Patents by Inventor Anne Freimoser-Grundschober

Anne Freimoser-Grundschober has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220169748
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: February 11, 2022
    Publication date: June 2, 2022
    Inventors: Christian KLEIN, Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Sylvia HERTER, Joaquin ARRIBAS, Rocio VICARIO
  • Patent number: 11332545
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: May 17, 2022
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Publication number: 20220010015
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: June 17, 2021
    Publication date: January 13, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Alejandro CARPY GUTIERREZ CIRLOS, Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Christiane NEUMANN, Pablo Umaña
  • Publication number: 20220010014
    Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: June 17, 2021
    Publication date: January 13, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anne Freimoser-Grundschober, Maria Valeria Gonzalez Nicolini, Ralf Hosse, Alexander Knaupp, Ekkehard Moessner, Wolfgang Richter, Halina Trochanowska, Pablo Umaña, Christian Klein, Inja Waldhauer
  • Publication number: 20210403562
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 30, 2021
    Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, Inja WALDHAUER, Wolfgang RICHTER, Alexander KNAUPP, Halina TROCHANOWSKA
  • Publication number: 20210355234
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: July 28, 2021
    Publication date: November 18, 2021
    Inventors: Christian KLEIN, Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Sylvia HERTER, Joaquin ARRIBAS, Rocio VICARIO
  • Patent number: 11111312
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 7, 2021
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Publication number: 20210101996
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Application
    Filed: December 10, 2020
    Publication date: April 8, 2021
    Inventors: Christian KLEIN, Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Sylvia HERTER, Joaquin ARRIBAS, Rocio VICARIO
  • Publication number: 20210070873
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Application
    Filed: November 4, 2020
    Publication date: March 11, 2021
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Patent number: 10882918
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: January 5, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Marina Bacac, Anne Freimoser-Grundschober, Sylvia Herter, Joaquin Arribas, Rocio Vicario
  • Patent number: 10851171
    Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: December 1, 2020
    Assignee: ENGMAB SARL
    Inventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
  • Publication number: 20200283545
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: March 17, 2020
    Publication date: September 10, 2020
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20200270347
    Abstract: The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: December 19, 2019
    Publication date: August 27, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Anne FREIMOSER-GRUNDSCHOBER, Thomas HOFER, Ralf HOSSE, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMAÑA, lnja WALDHAUER, Wolfgang Richter, Alexander KNAUPP, Halina TROCHANOWSKA
  • Publication number: 20200255521
    Abstract: A bispecific antibody specifically binding to the two targets human CD3? (further named also as “CD3”) and the extracellular domain of human ROR1 (further named also as “ROR1”), characterized in that the bispecific antibody does not internalize in a cell based assay at 37° C. during 2 hrs, using ROR1-positive B-CLL cells and used at an antibody concentration of 1 nM, whereby not internalize means, that the mean fluorescence intensity (MFI), as detected by flow cytometry, of a bispecific antibody upon binding to ROR1-positive primary B-CLL cells measured at time 0 is not reduced for more than 50%, preferably not more than 30% when re-measured after a 2 hr-incubation at 37° C. and which is useful for the treatment of B-cell malignancies like Chronic Lymphocytic Leukemia or B-cell disorders expressing ROR1 and ROR1-positive solid tumors.
    Type: Application
    Filed: January 27, 2020
    Publication date: August 13, 2020
    Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Tanja Fauti, Ramona Murr, Christian Klein, Pablo Umana, Samuel Moser
  • Patent number: 10683369
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: June 16, 2020
    Assignee: EngMab Sàrl
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20200079873
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Application
    Filed: April 8, 2019
    Publication date: March 12, 2020
    Applicant: Roche Glycart AG
    Inventors: Marina BACAC, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Valeria G. NICOLINI, Pablo UMANA
  • Patent number: 10577429
    Abstract: The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 3, 2020
    Assignee: ROCHE GLYCART AG
    Inventors: Marina Bacac, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Publication number: 20190352427
    Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 21, 2019
    Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Duerner, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
  • Publication number: 20190322765
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 24, 2019
    Applicant: Roche Glycart AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana
  • Patent number: 10323098
    Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the ?-subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: June 18, 2019
    Assignee: ROCHE GLYCART AG
    Inventors: Oliver Ast, Peter Bruenker, Anne Freimoser-Grundschober, Sylvia Herter, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Valeria G. Nicolini, Pablo Umana